Gut Microbiota-Activated Prodrugs: Enzymatic Mechanisms, Precision Design, Interindividual Variability, and Translational Challenges

The gut microbiota is a metabolically active biocatalytic system capable of transforming orally administered xenobiotics through reduction, hydrolysis, deconjugation, and related reactions. Among the most therapeutically tractable applications is the deliberate use of these reactions to activate prodrugs in the gastrointestinal tract. This review applies a strict mechanistic criterion: microbial metabolism must constitute a necessary or deliberately engineered step in generating the active therapeutic moiety. Under this definition, microbiota-activated prodrugs are distinguished from microbiota-mediated drug metabolism, microbiota-targeting interventions, microbiota-assisted delivery, and pH- or reactive oxygen species-responsive systems that do not require microbial chemical activation. This review synthesizes the enzymatic basis of activation, emphasizing azoreductases, β-glucuronidases, reductases, glycosidases, and microbial esterases; defines precision-design principles that prioritize functional rather than taxonomic targets; and examines how interindividual variation in enzyme abundance, expression, and activity can alter prodrug conversion. This review then proposes a causal-validation ladder linking purified enzymes and defined strains to donor microbiota, physiologically relevant gut models, gnotobiotic systems, and quantitative pharmacokinetic/pharmacodynamic studies. Finally, this review discusses companion functional diagnostics, ecological and manufacturing constraints, prospective patient stratification, and enzyme-prodrug co-design. By shifting the field from taxonomic correlation toward mechanism-based functional phenotyping, this review provides a practical framework for developing robust, patient-stratified microbiota-activated therapies in clinical development.